Amgen, a Thousand Oaks, Calif.-based biotechnology firm, said it entered into a definitive agreement to acquire DeCode Genetics, a biopharmaceutical company in Reykjavik, Iceland, that focuses on human genetics research, in a $415 million cash deal.
FULL STORY »